Published in Can J Gastroenterol on December 01, 2007
Primary biliary cirrhosis. Semin Immunopathol (2009) 1.46
Red Blood Cell Distribution Width to Platelet Ratio is Related to Histologic Severity of Primary Biliary Cirrhosis. Medicine (Baltimore) (2016) 0.80
Quantitative assessment of the elasticity values of liver with shear wave ultrasonographic elastography. Indian J Med Res (2013) 0.79
Ultrasound-based elastography for the diagnosis of portal hypertension in cirrhotics. World J Gastroenterol (2015) 0.78
Natural history and management of primary biliary cirrhosis. Hepat Med (2012) 0.77
Evaluating the risk of hepatocellular carcinoma in patients with prominently elevated liver stiffness measurements by FibroScan: a multicentre study. HPB (Oxford) (2016) 0.75
Intestinal parasitic infection among Egyptian children with chronic liver diseases. J Parasit Dis (2013) 0.75
An MLP classifier for prediction of HBV-induced liver cirrhosis using routinely available clinical parameters. Dis Markers (2013) 0.75
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (1996) 12.47
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology (2005) 9.44
Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol (2003) 9.19
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology (2005) 5.93
Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut (2005) 5.20
One-second needle biopsy of the liver. Gastroenterology (1958) 3.86
Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet (1986) 3.64
Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology (2005) 3.63
Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology (2000) 3.49
Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl (2006) 3.29
Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology (2006) 3.19
Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol (2006) 2.44
Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol (2006) 2.37
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology (2006) 2.21
Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr (2006) 1.87
Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate. Aliment Pharmacol Ther (2006) 0.84
[Evaluation of liver fibrosis in clinical practice]. Recenti Prog Med (2006) 0.79
Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature (1996) 8.02
Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet (1997) 3.68
Albumin messenger RNA as a marker of circulating hepatocytes in hepatocellular carcinoma. Gastroenterology (1994) 2.62
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut (2005) 2.39
Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med (1994) 2.31
Creatine kinase-BB: a marker of liver sinusoidal damage in ischemia-reperfusion. Hepatology (1993) 2.23
Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology (1998) 2.06
Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology (1999) 2.05
Differential HFE allele expression in hemochromatosis heterozygotes. Gastroenterology (2000) 2.04
Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol (2001) 1.98
A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med (1991) 1.92
Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology (1998) 1.85
Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology (1988) 1.79
Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology (1997) 1.63
Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am J Pathol (1999) 1.58
A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology (1984) 1.56
MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology (2001) 1.55
Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? J Hepatol (2001) 1.54
Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet (1987) 1.52
Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology (1992) 1.43
Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol (2010) 1.42
Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Liver Transpl Surg (1999) 1.41
Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol (1993) 1.39
Choledocho-ureteral anastomosis in the rat. A new experimental model of long-term, total, internal bile diversion. J Hepatol (1993) 1.39
Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem (1996) 1.38
PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest (2000) 1.32
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat (2007) 1.29
Hepatic stellate cell proliferation is an early platelet-derived growth factor-mediated cellular event in rat cholestatic liver injury. Lab Invest (2001) 1.27
Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol (1994) 1.26
Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C. J Viral Hepat (2011) 1.24
Fetal microchimerism in primary biliary cirrhosis. J Hepatol (2000) 1.20
Risk factors for hepatitis C virus infection in hepatitis C virus antibody ELISA-positive blood donors according to RIBA-2 status: a case-control survey. Hepatology (1993) 1.12
Pharmacological effect of somatostatin on bile secretion in man. Digestion (1989) 1.11
The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology (2000) 1.06
Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology (1992) 1.06
Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clin Pharmacol Ther (1990) 1.04
Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol (2000) 1.04
Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol (1994) 1.03
Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. Hepatology (1985) 1.03
Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology (1990) 1.02
Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol (1995) 1.01
Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol (1990) 1.00
Liver adenoma and focal nodular hyperplasia in a man with high endogenous sex steroids. Gastroenterology (1987) 0.99
Serum hyaluronan as a marker of liver fibrosis. J Hepatol (1995) 0.97
Gender and liver: is the liver stiffness weaker in weaker sex? Hepatology (2006) 0.96
Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology (1993) 0.96
Notch3 mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a mendelian condition causing stroke and vascular dementia. Ann N Y Acad Sci (1997) 0.96
Bile acid transport and regulating functions in the human biliary epithelium. Hepatology (2001) 0.95
Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology (1999) 0.95
Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol (2001) 0.95
[Rectal adenocarcinoma in association with lymphoma ("collision tumor")]. Gastroenterol Clin Biol (1990) 0.95
Absence of anti-LKM-1 antibody in hepatitis C viral infection in the United States of America. J Viral Hepat (1995) 0.94
Effect of lysine acetylsalicylate on biliary lipid secretion in dogs. Clin Sci Mol Med (1975) 0.93
Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology (1996) 0.92
Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology (1990) 0.92
Circulating albumin messenger RNA in hepatocellular carcinoma: results of a multicenter prospective study. Hepatology (1997) 0.90
[Celiac disease in adults. (48 cases) I. Anatomo-clinical, biological and radiological study; its course under a non-gluten diet]. Arch Fr Mal App Dig (1975) 0.90
[Tienilic acid-induced hepatitis associated with liver/kidney microsomal antibody (author's transl)]. Nouv Presse Med (1980) 0.89
Expression of blood group antigens including HLA markers in human adult liver. Tissue Antigens (1986) 0.89
Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology (1993) 0.88
Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. Hepatology (1997) 0.88
Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: a prospective study of twenty-seven cases in cirrhotic patients. Hepatology (1990) 0.88
Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology (2001) 0.88
Endothelin-1 secretion by human gallbladder epithelial cells in primary culture. Lab Invest (1993) 0.87
Effects of ursodeoxycholic acid and chenodeoxycholic acid on human hepatocytes in primary culture. Hepatology (1995) 0.87
Comparison of a new method for the direct and simultaneous assessment of LDL- and HDL-cholesterol with ultracentrifugation and established methods. Clin Chem (2000) 0.87
Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J Pharmacol Exp Ther (1988) 0.86
Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterology (1992) 0.86
Metabolism of alpha-ketoisocaproic acid in isolated perfused liver of cirrhotic rats. Am J Physiol (1995) 0.85
Bile acids modulate the interferon signalling pathway. Hepatology (1999) 0.85
Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology (1994) 0.85
Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Hepatology (1990) 0.85
Long-term follow-up after neoplastic seeding complicating percutaneous ethanol injection for treatment of hepatocellular carcinoma. Eur Radiol (2001) 0.84
[Drug-induced hepatotoxicity. The 13th updated edition of the bibliographic database of drug-related liver injuries and responsible drugs]. Gastroenterol Clin Biol (2000) 0.84
Cold preservation injury in rat liver: effect of liposomally-entrapped adenosine triphosphate. J Hepatol (2000) 0.84
Liver ganglioside storage after perhexiline maleate. Lancet (1977) 0.84
Influence of bile acids upon biliary cholesterol and phospholipid secretion in the dog. Eur J Clin Invest (1976) 0.84
Effect of cholestasis and bile acids on interferon-induced 2',5'-adenylate synthetase and NK cell activities. Gastroenterology (1995) 0.83
Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group. J Hepatol (1990) 0.83
The influence of vasoactive agents on metabolic activity of the liver in cirrhosis: a study of the effects of posterior pituitary extract, vasopressin, and somatostatin. Hepatology (1984) 0.83
Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology (1996) 0.83
Fasting serum bile acid level in cirrhosis. A semi-quantitative index of hepatic function. J Hepatol (1985) 0.82
[Hepatic lesions due to perhexiline maleate (author's transl)]. Gastroenterol Clin Biol (1978) 0.82
Ursodeoxycholic acid for primary biliary cirrhosis. Lancet (2000) 0.82
Effect of vasodilators on hepatic microcirculation in cirrhosis: a study in the isolated perfused rat liver. Hepatology (1989) 0.82
Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment. Gut (1989) 0.82
[Chylous ascites in cirrhosis. Retrospective study of 20 cases]. Gastroenterol Clin Biol (1990) 0.81
Hepatic extraction of adriamycin in patients with hepatocellular carcinoma. Eur J Cancer Clin Oncol (1984) 0.81
Activity of human adenylate cyclase from human fat cell membranes. Biomedicine (1975) 0.81
Antimitochondrial antibodies in patients with chronic hepatitis C. Liver (1996) 0.81
Effect of D-tryptophan-6-luteinizing hormone-releasing hormone on the tumoral growth and plasma sex steroid levels in cirrhotic patients with hepatocellular carcinoma. Hepatology (1989) 0.81
[Complications due to peripheral venous catheterization. Prospective study]. Presse Med (2003) 0.80
Antineutrophil cytoplasmic autoantibodies in autoimmune liver and inflammatory bowel diseases. Liver (1996) 0.80
Phase I and phase II drug-metabolizing enzymes are expressed and heterogeneously distributed in the biliary epithelium. Hepatology (1999) 0.80